US FDA accepts Pfizer's neurodegenerative disease drug NDA
This article was originally published in Scrip
Executive Summary
After being snubbed by the US FDA last year, Pfizer's new drug application (NDA) for tafamidis meglumine was accepted by the agency as a treatment for transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare, progressive fatal neurodegenerative disease, which affects about 8,000 patients worldwide.